Imagine you have a big jigsaw puzzle of the human body. You start with the gut, then move to the brain, and suddenly realize there is a mysterious connection between them – the microbiota-gut-brain axis (MGBA)! Well, this connection has caught the attention of researchers investigating Alzheimer’s disease (AD). They’ve been studying this fascinating link like experts analyzing a treasure map! Using a special software called CiteSpace, they analyzed over 600 AD-related articles from 2012 to 2021 to uncover exciting trends and research hotspots. The results showed that the research on MGBA in AD has been steadily increasing, with close collaborations between countries. The interdisciplinary nature of the research involved disciplines like neuroscience, pharmacy, and microbiology. The focus has been unraveling the connection between MGBA and AD symptoms. Keywords like new technologies, anterior cingulate cortex, and dysbiosis have fueled curiosity within this field. Although no major breakthroughs have been made in the past decade, this study highlights the need for multidisciplinary approaches and international collaboration to unlock new frontiers in understanding AD through the MGBA. So put on your lab coat and goggles, and dive into this research adventure!
BackgroundRecently, research on the microbiota-gut-brain axis (MGBA) has received increasing attention, and the number of studies related to Alzheimer’s disease (AD) has increased rapidly, but there is currently a lack of summary of MGBA in AD.ObjectiveTo capture research hotspots, grasp the context of disciplinary research, and explore future research development directions.MethodsIn the core dataset of Web of Science, documents are searched according to specific subject words. CiteSpace software is used to perform statistical analysis on measurement indicators such as the number of published papers, publishing countries, institutions, subject areas, authors, cocited journals, and keywords, and to visualize of a network of relevant content elements.ResultsThe research of MGBA in AD has shown an upward trend year by year, and the cooperation between countries is relatively close, and mainly involves the intersection of neuroscience, pharmacy, and microbiology. This research focuses on the relationship between MGBA and AD symptoms. Keyword hotspots are closely related to new technologies. Alzheimer’s disease, anterior cingulate cortex, inflammatory degeneration, dysbiosis, and other research are the focus of this field.ConclusionThe study revealed that the research and development of MGBA in AD rapidly progressed, but no breakthrough has been made in the past decade, it still needs to be closely combined with multidisciplinary technology to grasp the frontier hotspots. Countries should further strengthen cooperation, improve the disciplinary system, and increase the proportion of empirical research in all research.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.